In this phase 2 study, researchers aimed to evaluate the effectiveness of tyrosine kinase inhibition in relapsed or refractory germ cell tumors.

Based on the NCCN 1.2026 guidelines for the management of CSI seminoma, surveillance is strongly preferred for pT1-pT3 tumors, and the NCCN does not recommend risk-adapted treatment for CSI seminoma ...

The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a ...

In human cells, DNA carries chemical or "epigenetic" marks that decide how genes will be used in different tissues. Yet in a ...

Non-seminoma is a type of germ-cell testicular cancer. Treatment may include surgery to remove a testicle, lymph node removal, and chemotherapy. Most cases of testicular cancer develop from germ cells ...

Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors Clinical trials frequently include ...

Innovations in the care of adolescent and young adult (AYA) germ cell tumors (GCTs) are needed for one of the most common AYA cancers for which treatment has not significantly changed for several ...

Can fragments of tumor DNA in the blood predict whether chemotherapy will be effective? Researchers at the Princess Máxima Center investigated this question together with experts from Italy and ...

Te Whero, a New Zealand social media sensation, died on Feb. 13 ...